Date: 2017-04-10
Type of information: Private placement
Company: Adaptimmune (UK)
Investors: Matrix Capital (USA - MA)
Amount: $42 million
Funding type: private placement
Planned used: Net proceeds of the offering will be used to advance the company’s wholly-owned pipeline of SPEAR T-cell candidates through clinical trials as well as for other general corporate purposes.
Others:
- • On April 10, 2017, Adaptimmune Therapeutics announced the closing of its previously announced registered direct offering of its American Depositary Shares following its entry into a definitive agreement with Matrix Capital Management to purchase an aggregate of approximately US$42,000,000 of its ADSs. Adaptimmune sold 7,000,000 ADSs at a price of $6.00 per ADS. Net proceeds of the offering are approximately $42 million, which combined with the $62 million raised in the company’s public offering that closed on March 27, takes the total aggregate net proceeds to over $100 million.
- • On April 5, 2017, Adaptimmune Therapeutics announced that it has entered into a definitive agreement with Matrix Capital Management Company to purchase an aggregate of approximately US$42,000,000 of its American Depositary Shares in a registered direct offering. The transaction was completed from the company’s shelf registration at $6.00 per ADS, a premium of approximately 3% to the closing ADS trade price on April 3rd. The closing of this offering is expected to take place on or about April 10, 2017, subject to the satisfaction of customary closing conditions.
- Matrix is an investment fund manager based in Waltham, MA with a 17-year track record investing primarily in public companies. The fund holds a concentrated portfolio of high-conviction, uniquely diligenced investment ideas, with a focus on growth companies in enterprise software, life sciences, consumer internet and media, among other sectors.
Therapeutic area: Cancer - Oncology
Is general: Yes
